JP2014513704A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014513704A5 JP2014513704A5 JP2014510768A JP2014510768A JP2014513704A5 JP 2014513704 A5 JP2014513704 A5 JP 2014513704A5 JP 2014510768 A JP2014510768 A JP 2014510768A JP 2014510768 A JP2014510768 A JP 2014510768A JP 2014513704 A5 JP2014513704 A5 JP 2014513704A5
- Authority
- JP
- Japan
- Prior art keywords
- nhr
- group
- alkyl
- amino
- pyridazin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001424 substituent group Chemical group 0.000 claims description 111
- 125000005843 halogen group Chemical group 0.000 claims description 74
- 125000003118 aryl group Chemical group 0.000 claims description 71
- 150000001875 compounds Chemical class 0.000 claims description 64
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 52
- 125000001072 heteroaryl group Chemical group 0.000 claims description 47
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 44
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 41
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 32
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 32
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 32
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 30
- 125000006584 (C3-C10) heterocycloalkyl group Chemical group 0.000 claims description 29
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 22
- 239000012453 solvate Substances 0.000 claims description 22
- 150000001204 N-oxides Chemical class 0.000 claims description 21
- -1 C 1 -C 6 alkyl- Chemical group 0.000 claims description 12
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 11
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 8
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 claims description 8
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- 229910052740 iodine Inorganic materials 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 125000005246 nonafluorobutyl group Chemical group FC(F)(F)C(F)(F)C(F)(F)C(F)(F)* 0.000 claims description 4
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims description 4
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical group OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 206010027476 Metastases Diseases 0.000 claims 6
- 230000024932 T cell mediated immunity Effects 0.000 claims 6
- 230000010261 cell growth Effects 0.000 claims 6
- 230000004663 cell proliferation Effects 0.000 claims 6
- 230000001413 cellular effect Effects 0.000 claims 6
- 230000028709 inflammatory response Effects 0.000 claims 6
- 230000009401 metastasis Effects 0.000 claims 6
- 230000004083 survival effect Effects 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- DUUUNXBJKXZKMJ-UHFFFAOYSA-N 2-[[3-(1-benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]amino]-1-(oxan-4-yl)ethanol Chemical compound C1=CC2=NC=C(C=3OC4=CC=CC=C4C=3)N2N=C1NCC(O)C1CCOCC1 DUUUNXBJKXZKMJ-UHFFFAOYSA-N 0.000 claims 2
- JPWHSYJJZACBLR-UHFFFAOYSA-N 2-[[3-(1-benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]amino]-1-cyclopropylethanol Chemical compound C1=CC2=NC=C(C=3OC4=CC=CC=C4C=3)N2N=C1NCC(O)C1CC1 JPWHSYJJZACBLR-UHFFFAOYSA-N 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 208000002699 Digestive System Neoplasms Diseases 0.000 claims 2
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010027465 Metastases to skin Diseases 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 206010029098 Neoplasm skin Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 201000011523 endocrine gland cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000037841 lung tumor Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 230000037361 pathway Effects 0.000 claims 2
- 208000023958 prostate neoplasm Diseases 0.000 claims 2
- 201000004477 skin sarcoma Diseases 0.000 claims 2
- REAUMEFIVWHGEV-KRWDZBQOSA-N (1R)-2-[[3-(4-methoxyfuro[3,2-c]pyridin-2-yl)imidazo[1,2-b]pyridazin-6-yl]amino]-1-phenylethanol Chemical compound C1([C@@H](O)CNC=2C=CC3=NC=C(N3N=2)C=2OC=3C=CN=C(C=3C=2)OC)=CC=CC=C1 REAUMEFIVWHGEV-KRWDZBQOSA-N 0.000 claims 1
- AEWCZIWKJPNHNP-SFHVURJKSA-N (1r)-2-[[3-(1-benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]amino]-1-phenylethanol Chemical compound C1([C@H](CNC2=NN3C(C=4OC5=CC=CC=C5C=4)=CN=C3C=C2)O)=CC=CC=C1 AEWCZIWKJPNHNP-SFHVURJKSA-N 0.000 claims 1
- RGXKEDZRUAEVNO-KRWDZBQOSA-N (1r)-2-[[3-(1-benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]amino]-1-pyridin-3-ylethanol Chemical compound C1([C@H](CNC2=NN3C(C=4OC5=CC=CC=C5C=4)=CN=C3C=C2)O)=CC=CN=C1 RGXKEDZRUAEVNO-KRWDZBQOSA-N 0.000 claims 1
- AEWCZIWKJPNHNP-GOSISDBHSA-N (1s)-2-[[3-(1-benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]amino]-1-phenylethanol Chemical compound C1([C@@H](CNC2=NN3C(C=4OC5=CC=CC=C5C=4)=CN=C3C=C2)O)=CC=CC=C1 AEWCZIWKJPNHNP-GOSISDBHSA-N 0.000 claims 1
- REAUMEFIVWHGEV-QGZVFWFLSA-N (1s)-2-[[3-(4-methoxyfuro[3,2-c]pyridin-2-yl)imidazo[1,2-b]pyridazin-6-yl]amino]-1-phenylethanol Chemical compound C1([C@H](O)CNC=2C=CC3=NC=C(N3N=2)C=2OC=3C=CN=C(C=3C=2)OC)=CC=CC=C1 REAUMEFIVWHGEV-QGZVFWFLSA-N 0.000 claims 1
- GQBQUHIYUGPPAX-LLVKDONJSA-N (2R)-1-[[3-(1-benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]amino]propan-2-ol Chemical compound C[C@@H](O)CNC1=NN2C(C=C1)=NC=C2C1=CC2=C(O1)C=CC=C2 GQBQUHIYUGPPAX-LLVKDONJSA-N 0.000 claims 1
- GQBQUHIYUGPPAX-NSHDSACASA-N (2S)-1-[[3-(1-benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]amino]propan-2-ol Chemical compound C[C@H](O)CNC1=NN2C(C=C1)=NC=C2C1=CC2=C(O1)C=CC=C2 GQBQUHIYUGPPAX-NSHDSACASA-N 0.000 claims 1
- XXOAIQJDMSTOLB-SFHVURJKSA-N (2S)-2-[[3-(1-benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]amino]-3-(1H-indol-3-yl)propan-1-ol Chemical compound OC[C@H](CC1=CNC2=C1C=CC=C2)NC1=NN2C(C=C1)=NC=C2C1=CC2=C(O1)C=CC=C2 XXOAIQJDMSTOLB-SFHVURJKSA-N 0.000 claims 1
- HPIBHPKOFWESRC-SFHVURJKSA-N (2S)-2-[[3-(1-benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]amino]-3-phenylpropan-1-ol Chemical compound OC[C@H](CC1=CC=CC=C1)NC1=NN2C(C=C1)=NC=C2C1=CC2=C(O1)C=CC=C2 HPIBHPKOFWESRC-SFHVURJKSA-N 0.000 claims 1
- IWISQJRXUSVULY-LLVKDONJSA-N (2r)-2-[[3-(1-benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]amino]propan-1-ol Chemical compound C1=CC=C2OC(C3=CN=C4C=CC(=NN43)N[C@@H](CO)C)=CC2=C1 IWISQJRXUSVULY-LLVKDONJSA-N 0.000 claims 1
- FMZSPBSNIGWHLI-GFCCVEGCSA-N (2r)-3-[[3-(1-benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]amino]propane-1,2-diol Chemical compound C1=CC=C2OC(C3=CN=C4C=CC(=NN43)NC[C@@H](O)CO)=CC2=C1 FMZSPBSNIGWHLI-GFCCVEGCSA-N 0.000 claims 1
- DCPLJLUNNRCGLN-ZDUSSCGKSA-N (2s)-2-[[3-(1-benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]amino]butan-1-ol Chemical compound C1=CC=C2OC(C3=CN=C4C=CC(=NN43)N[C@H](CO)CC)=CC2=C1 DCPLJLUNNRCGLN-ZDUSSCGKSA-N 0.000 claims 1
- FMZSPBSNIGWHLI-LBPRGKRZSA-N (2s)-3-[[3-(1-benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]amino]propane-1,2-diol Chemical compound C1=CC=C2OC(C3=CN=C4C=CC(=NN43)NC[C@H](O)CO)=CC2=C1 FMZSPBSNIGWHLI-LBPRGKRZSA-N 0.000 claims 1
- VIVRNAFMYBZDMK-UHFFFAOYSA-N 1-[3-[[3-(1-benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]amino]-2-hydroxypropyl]pyrrolidin-2-one Chemical compound C1=CC2=NC=C(C=3OC4=CC=CC=C4C=3)N2N=C1NCC(O)CN1CCCC1=O VIVRNAFMYBZDMK-UHFFFAOYSA-N 0.000 claims 1
- WUPHEESAOBFQHE-UHFFFAOYSA-N 1-[[3-(1-benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]amino]-2-phenylpropan-2-ol Chemical compound C1=CC2=NC=C(C=3OC4=CC=CC=C4C=3)N2N=C1NCC(O)(C)C1=CC=CC=C1 WUPHEESAOBFQHE-UHFFFAOYSA-N 0.000 claims 1
- ZDUTXKMGGQLSCI-UHFFFAOYSA-N 1-[[3-(1-benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]amino]-3,3-dimethylbutan-2-ol Chemical compound C1=CC=C2OC(C3=CN=C4C=CC(=NN43)NCC(O)C(C)(C)C)=CC2=C1 ZDUTXKMGGQLSCI-UHFFFAOYSA-N 0.000 claims 1
- HVZWKUPNOMUBND-UHFFFAOYSA-N 1-[[3-(1-benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]amino]-3-methylbutan-2-ol Chemical compound C1=CC=C2OC(C3=CN=C4C=CC(=NN43)NCC(O)C(C)C)=CC2=C1 HVZWKUPNOMUBND-UHFFFAOYSA-N 0.000 claims 1
- BRQIZZYMSMRQPW-UHFFFAOYSA-N 1-[[3-(1-benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]amino]-3-morpholin-4-ylpropan-2-ol Chemical compound C1=CC2=NC=C(C=3OC4=CC=CC=C4C=3)N2N=C1NCC(O)CN1CCOCC1 BRQIZZYMSMRQPW-UHFFFAOYSA-N 0.000 claims 1
- GWCDIHMLXPHIJH-UHFFFAOYSA-N 1-[[3-(1-benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]amino]-3-piperidin-1-ylpropan-2-ol Chemical compound C1=CC2=NC=C(C=3OC4=CC=CC=C4C=3)N2N=C1NCC(O)CN1CCCCC1 GWCDIHMLXPHIJH-UHFFFAOYSA-N 0.000 claims 1
- FXYSPNIUQLRBDR-UHFFFAOYSA-N 1-[[3-(1-benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]amino]-3-pyrrolidin-1-ylpropan-2-ol Chemical compound C1=CC2=NC=C(C=3OC4=CC=CC=C4C=3)N2N=C1NCC(O)CN1CCCC1 FXYSPNIUQLRBDR-UHFFFAOYSA-N 0.000 claims 1
- TZLKXQJTRKXXGE-UHFFFAOYSA-N 1-[[3-(1-benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]amino]butan-2-ol Chemical compound C1=CC=C2OC(C3=CN=C4C=CC(=NN43)NCC(O)CC)=CC2=C1 TZLKXQJTRKXXGE-UHFFFAOYSA-N 0.000 claims 1
- HODSRCMIWTUXOT-UHFFFAOYSA-N 1-[[3-(4-methoxyfuro[3,2-c]pyridin-2-yl)imidazo[1,2-b]pyridazin-6-yl]amino]butan-2-ol Chemical compound N1=CC=C2OC(C3=CN=C4C=CC(=NN43)NCC(O)CC)=CC2=C1OC HODSRCMIWTUXOT-UHFFFAOYSA-N 0.000 claims 1
- YIBLWSBTKLZNDK-UHFFFAOYSA-N 1-amino-3-[[3-(1-benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]amino]propan-2-ol Chemical compound C1=CC=C2OC(C3=CN=C4C=CC(=NN43)NCC(O)CN)=CC2=C1 YIBLWSBTKLZNDK-UHFFFAOYSA-N 0.000 claims 1
- OLRVMPNQOMVXSW-UHFFFAOYSA-N 1-cyclopropyl-2-[[3-(4-methoxyfuro[3,2-c]pyridin-2-yl)imidazo[1,2-b]pyridazin-6-yl]amino]ethanol Chemical compound C=1C=2C(OC)=NC=CC=2OC=1C(N1N=2)=CN=C1C=CC=2NCC(O)C1CC1 OLRVMPNQOMVXSW-UHFFFAOYSA-N 0.000 claims 1
- OSGKFCOGCDQATF-UHFFFAOYSA-N 2-[[3-(1-benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]amino]-1-(4-fluorophenyl)ethanol Chemical compound C1=CC2=NC=C(C=3OC4=CC=CC=C4C=3)N2N=C1NCC(O)C1=CC=C(F)C=C1 OSGKFCOGCDQATF-UHFFFAOYSA-N 0.000 claims 1
- ALSWKDGXOWKHNH-UHFFFAOYSA-N 2-[[3-(1-benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]amino]-1-pyridin-2-ylethanol Chemical compound C1=CC2=NC=C(C=3OC4=CC=CC=C4C=3)N2N=C1NCC(O)C1=CC=CC=N1 ALSWKDGXOWKHNH-UHFFFAOYSA-N 0.000 claims 1
- QCYKKKBDJMYMKY-UHFFFAOYSA-N 2-[[3-(1-benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]amino]ethanol Chemical compound C1=CC=C2OC(C3=CN=C4C=CC(=NN43)NCCO)=CC2=C1 QCYKKKBDJMYMKY-UHFFFAOYSA-N 0.000 claims 1
- VQJDTFPJDFMKNW-UHFFFAOYSA-N 2-[[3-(1-benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]amino]hexan-1-ol Chemical compound CCCCC(CO)NC1=NN2C(C=C1)=NC=C2C1=CC2=C(O1)C=CC=C2 VQJDTFPJDFMKNW-UHFFFAOYSA-N 0.000 claims 1
- IWISQJRXUSVULY-UHFFFAOYSA-N 2-[[3-(1-benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]amino]propan-1-ol Chemical compound C1=CC=C2OC(C3=CN=C4C=CC(=NN43)NC(CO)C)=CC2=C1 IWISQJRXUSVULY-UHFFFAOYSA-N 0.000 claims 1
- SBQAUBVLQRGQPC-UHFFFAOYSA-N 2-[[3-(1-benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]amino]propane-1,3-diol Chemical compound OCC(CO)NC1=NN2C(C=C1)=NC=C2C1=CC2=C(O1)C=CC=C2 SBQAUBVLQRGQPC-UHFFFAOYSA-N 0.000 claims 1
- PLFZEAHFYFOFAU-UHFFFAOYSA-N 2-[[3-(4-methoxyfuro[3,2-c]pyridin-2-yl)imidazo[1,2-b]pyridazin-6-yl]amino]-1-(oxan-4-yl)ethanol Chemical compound C=1C=2C(OC)=NC=CC=2OC=1C(N1N=2)=CN=C1C=CC=2NCC(O)C1CCOCC1 PLFZEAHFYFOFAU-UHFFFAOYSA-N 0.000 claims 1
- KWMJEVFRHBAIFX-UHFFFAOYSA-N 3-[[3-(1-benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]amino]-2,2-dimethylpropan-1-ol Chemical compound CC(C)(CO)CNC1=NN2C(C=C1)=NC=C2C1=CC2=C(O1)C=CC=C2 KWMJEVFRHBAIFX-UHFFFAOYSA-N 0.000 claims 1
- MHYZDKRZYATREZ-UHFFFAOYSA-N 3-[[3-(1-benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]amino]propan-1-ol Chemical compound C1=CC=C2OC(C3=CN=C4C=CC(=NN43)NCCCO)=CC2=C1 MHYZDKRZYATREZ-UHFFFAOYSA-N 0.000 claims 1
- FMZSPBSNIGWHLI-UHFFFAOYSA-N 3-[[3-(1-benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]amino]propane-1,2-diol Chemical compound C1=CC=C2OC(C3=CN=C4C=CC(=NN43)NCC(O)CO)=CC2=C1 FMZSPBSNIGWHLI-UHFFFAOYSA-N 0.000 claims 1
- BXRRLRQODYQGEO-UHFFFAOYSA-N 4-[[3-(1-benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]amino]butan-2-ol Chemical compound CC(O)CCNC1=NN2C(C=C1)=NC=C2C1=CC2=C(O1)C=CC=C2 BXRRLRQODYQGEO-UHFFFAOYSA-N 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000004942 pyridazin-6-yl group Chemical group N1=NC=CC=C1* 0.000 claims 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 0 *C(*1)=C(*)C=C2*1C([N+]*)=C*2 Chemical compound *C(*1)=C(*)C=C2*1C([N+]*)=C*2 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11166426.4 | 2011-05-17 | ||
| EP11166426 | 2011-05-17 | ||
| PCT/EP2012/058931 WO2012156367A1 (en) | 2011-05-17 | 2012-05-14 | Amino-substituted imidazopyridazines as mknk1 kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014513704A JP2014513704A (ja) | 2014-06-05 |
| JP2014513704A5 true JP2014513704A5 (https=) | 2017-02-09 |
| JP6121991B2 JP6121991B2 (ja) | 2017-04-26 |
Family
ID=46124340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014510768A Active JP6121991B2 (ja) | 2011-05-17 | 2012-05-14 | Ｍｋｎｋ１キナーゼ阻害剤としてのアミノ置換イミダゾピリダジン |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20140288069A1 (https=) |
| EP (1) | EP2710004A1 (https=) |
| JP (1) | JP6121991B2 (https=) |
| CN (1) | CN103687858B (https=) |
| CA (1) | CA2836203A1 (https=) |
| WO (1) | WO2012156367A1 (https=) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012163942A1 (en) * | 2011-06-01 | 2012-12-06 | Bayer Intellectual Property Gmbh | Substituted aminoimidazopyridazines |
| UA117092C2 (uk) | 2011-09-06 | 2018-06-25 | Байєр Інтеллектуал Проперті Гмбх | Амінозаміщені імідазопіридазини |
| CA2849345A1 (en) * | 2011-09-23 | 2013-03-28 | Bayer Intellectual Property Gmbh | Substituted imidazopyridazines |
| CN104114559B (zh) * | 2011-12-12 | 2016-08-24 | 拜耳知识产权有限责任公司 | 氨基取代的咪唑并哒嗪 |
| ES2663609T3 (es) | 2012-03-29 | 2018-04-16 | Bayer Intellectual Property Gmbh | Imidazopiridazinas amino-sustituidas |
| EP2834245B1 (en) * | 2012-04-04 | 2017-12-13 | Bayer Pharma Aktiengesellschaft | Amino-substituted imidazopyridazines |
| RS58514B1 (sr) | 2012-06-13 | 2019-04-30 | Incyte Holdings Corp | Supstituisana triciklična jedinjenja kao inhibitori fgfr |
| ES2646916T3 (es) | 2012-11-19 | 2017-12-18 | Bayer Pharma Aktiengesellschaft | Aminoimidazopiridazinas como inhibidores de MKNK1 cinasa |
| JP6510419B2 (ja) * | 2012-12-17 | 2019-05-08 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 液晶ディスプレイ、およびホメオトロピック配列を有する液晶媒体 |
| ES2649156T3 (es) | 2013-01-14 | 2018-01-10 | Incyte Holdings Corporation | Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim |
| PE20191245A1 (es) | 2013-01-15 | 2019-09-18 | Incyte Holdings Corp | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim |
| WO2014118135A1 (en) * | 2013-01-30 | 2014-08-07 | Bayer Pharma Aktiengesellschaft | Amidoimidazopyridazines as mknk-1 kinase inhibitors |
| CA2899662A1 (en) | 2013-02-01 | 2014-08-07 | Bayer Pharma Aktiengesellschaft | Substituted pyrazolopyrimidinylamino-indazoles |
| HK1212699A1 (zh) * | 2013-02-20 | 2016-06-17 | 拜耳医药股份公司 | 作为mknk1抑制剂的取代的咪唑并[1，2-b]哒嗪类化合物 |
| PH12015502383B1 (en) | 2013-04-19 | 2023-02-03 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| EA201690458A1 (ru) | 2013-08-23 | 2016-07-29 | Инсайт Корпорейшн | Фуро- и тиенопиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы |
| CN105899512A (zh) | 2014-01-09 | 2016-08-24 | 拜耳医药股份公司 | 可用于治疗过度增殖性和/或血管生成疾病的酰胺基团取代的咪唑并哒嗪 |
| US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| TWI712601B (zh) | 2015-02-20 | 2020-12-11 | 美商英塞特公司 | 作為fgfr抑制劑之雙環雜環 |
| EP3285809B1 (en) | 2015-04-20 | 2019-09-11 | eFFECTOR Therapeutics, Inc. | Inhibitors of immune checkpoint modulators for use in treating cancer and infections |
| WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| TWI734699B (zh) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Ｐｉｍ激酶抑制劑之鹽 |
| US9920032B2 (en) | 2015-10-02 | 2018-03-20 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| WO2017117052A1 (en) | 2015-12-31 | 2017-07-06 | Effector Therapeutics, Inc. | Mnk biomarkers and uses thereof |
| WO2017157418A1 (en) | 2016-03-15 | 2017-09-21 | Bayer Pharma Aktiengesellschaft | Combination of mknk1-inhibitors |
| US20180072741A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyrimidine compounds and uses thereof |
| WO2018049214A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
| CN115819417A (zh) | 2016-09-09 | 2023-03-21 | 因赛特公司 | 作为hpk1调节剂的吡唑并吡啶衍生物及其用于治疗癌症的用途 |
| WO2018152220A1 (en) | 2017-02-15 | 2018-08-23 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| US10722495B2 (en) | 2017-09-08 | 2020-07-28 | Incyte Corporation | Cyanoindazole compounds and uses thereof |
| WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
| US10752635B2 (en) | 2018-02-20 | 2020-08-25 | Incyte Corporation | Indazole compounds and uses thereof |
| EP3755703B1 (en) | 2018-02-20 | 2022-05-04 | Incyte Corporation | N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as hpk1 inhibitors for treating cancer |
| US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
| AU2019262579B2 (en) | 2018-05-04 | 2024-09-12 | Incyte Corporation | Salts of an FGFR inhibitor |
| HRP20241288T1 (hr) | 2018-05-04 | 2024-12-06 | Incyte Corporation | Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju |
| US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
| WO2020068729A1 (en) | 2018-09-25 | 2020-04-02 | Incyte Corporation | Pyrazolo[4,3-d]pyrimidine compounds as alk2 abd/or fgfr modulators |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| BR112022002059A2 (pt) | 2019-08-06 | 2022-06-07 | Incyte Corp | Formas sólidas de um inibidor de hpk1 |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CA3157361A1 (en) | 2019-10-14 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| JP7832891B2 (ja) | 2019-12-04 | 2026-03-18 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤の誘導体 |
| CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2022221170A1 (en) | 2021-04-12 | 2022-10-20 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| US11939331B2 (en) | 2021-06-09 | 2024-03-26 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
| CA3220155A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4408047A (en) | 1980-03-28 | 1983-10-04 | Merck & Co., Inc. | Imidazodiazines |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| WO2003018020A1 (en) | 2001-08-23 | 2003-03-06 | Takeda Chemical Industries, Ltd. | Jnk inhibitors |
| EP1910369A1 (en) * | 2005-07-29 | 2008-04-16 | Astellas Pharma Inc. | Fused heterocycles as lck inhibitors |
| US20070049591A1 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Inhibitors of MAPK/Erk Kinase |
| DE102005042742A1 (de) | 2005-09-02 | 2007-03-08 | Schering Ag | Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
| US7750000B2 (en) * | 2005-09-02 | 2010-07-06 | Bayer Schering Pharma Ag | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments |
| US20070078136A1 (en) | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| CA2651898A1 (en) * | 2006-04-07 | 2007-10-18 | Develogen Aktiengesellschaft | Thienopyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions |
| DE102006029447A1 (de) | 2006-06-21 | 2007-12-27 | Bayer Schering Pharma Ag | Oxo-substituierte Imidazo[1,2b]pyridazine, deren Herstellung und Verwendung als Arzneimittel |
| EP1873157A1 (en) * | 2006-06-21 | 2008-01-02 | Bayer Schering Pharma Aktiengesellschaft | Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
| US20080039450A1 (en) * | 2006-06-22 | 2008-02-14 | Jensen Annika J | Compounds |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| EP1900739A1 (en) * | 2006-08-30 | 2008-03-19 | Cellzome Ag | Diazolodiazine derivatives as kinase inhibitors |
| CN101594909A (zh) * | 2006-09-07 | 2009-12-02 | 比奥根艾迪克Ma公司 | 用于治疗炎性病症、细胞增殖性失调、免疫失调的irak调节剂 |
| JP2010508315A (ja) | 2006-10-30 | 2010-03-18 | ノバルティス アーゲー | 抗炎症剤としてのヘテロ環式化合物 |
| WO2008058126A2 (en) | 2006-11-06 | 2008-05-15 | Supergen, Inc. | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors |
| WO2008072682A1 (ja) | 2006-12-15 | 2008-06-19 | Daiichi Sankyo Company, Limited | イミダゾ［１，２－ｂ］ピリダジン誘導体 |
| AR064420A1 (es) | 2006-12-21 | 2009-04-01 | Alcon Mfg Ltd | Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop). |
| EP2217601A1 (en) | 2007-11-08 | 2010-08-18 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Imidazopyridazines for use as protein kinase inhibitors |
-
2012
- 2012-05-14 US US14/118,519 patent/US20140288069A1/en not_active Abandoned
- 2012-05-14 CN CN201280035372.7A patent/CN103687858B/zh not_active Expired - Fee Related
- 2012-05-14 EP EP12721826.1A patent/EP2710004A1/en not_active Withdrawn
- 2012-05-14 CA CA2836203A patent/CA2836203A1/en not_active Abandoned
- 2012-05-14 WO PCT/EP2012/058931 patent/WO2012156367A1/en not_active Ceased
- 2012-05-14 JP JP2014510768A patent/JP6121991B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014513704A5 (https=) | ||
| JP7278359B2 (ja) | Ｓｈｐ２の活性を阻害するための化合物および組成物 | |
| JP7673041B2 (ja) | 治療薬としての細胞毒素のペプチドコンジュゲート | |
| JP2015537017A5 (https=) | ||
| JP2019518766A5 (https=) | ||
| JP2022515198A5 (https=) | ||
| KR102279999B1 (ko) | 선택적 에스트로겐 수용체 분해제로서의 벤조티오펜 유도체 및 그의 조성물 | |
| JP2020531447A5 (https=) | ||
| JP2014503567A5 (https=) | ||
| JP2010241830A5 (https=) | ||
| JP6824954B2 (ja) | ｍＩＤＨ１阻害剤としての５−ヒドロキシアルキルベンズイミダゾール | |
| JP2014503574A5 (https=) | ||
| JP7328323B2 (ja) | ＳＭＡＲＣＡ２／ＢＲＭ ＡＴＰａｓｅ阻害剤としての尿素化合物及び組成物 | |
| JP2008535903A5 (https=) | ||
| JP2020517616A5 (https=) | ||
| WO2016203404A1 (en) | Compounds and compositions for inhibiting the activity of shp2 | |
| KR20190041471A (ko) | 케모카인 수용체 조절제 및 이의 용도 | |
| JP2014520898A5 (https=) | ||
| JP2015522650A5 (https=) | ||
| JP2016514719A5 (https=) | ||
| JP2017503000A (ja) | Ｓｈｐ２の活性を阻害するための１−ピリダジン／トリアジン−３−イル−ピペラジン／ピペリジン／ピロリジン誘導体およびその組成物 | |
| JP2014510774A5 (https=) | ||
| JP2015512943A5 (https=) | ||
| JP2017511321A5 (https=) | ||
| JP2020536971A5 (https=) |